Company / Operating Income
Gilead Sciences Operating Income History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income
$10.0B
FY2025
5-year range
$1.7B / $10.0B
FY2021-FY2025
Trend
+503.0%
vs FY2024
Sector context
#2 of 204
Health Care
What the data says
Operating Income changed +503% YoY in FY2025, a notable deviation from the 9-year average annual change of +55%.
Based on SEC 10-K filings.
$10.0B in FY2025 with a 5-year CAGR of +19.7%. Ranks 2nd among 204 companies in Health Care.
Remained stable around $10.0B over the past 2 years.
Health Care sector context is included.
Operating Income over time
Growth rates
- 3-Year CAGR
- +35.0%
- 5-Year CAGR
- +19.7%
- 10-Year CAGR
- -
Sector benchmark
Top 1% in Health CareTop 1% of 204This company $10.0B Sector average $107.7M
▼
+9203.8% above sector average
Key checks
Key Insights
- 5-year CAGR of +19.7%, indicating consistent growth.
- In FY2025, operating income increased 503.0% year-over-year.
- Ranks #2 out of 204 companies in the Health Care sector.
- Peak operating income was recorded in FY2017.
Company context
Key Data Points
- Strong profit margin: 27.9%
- Strong return on equity: 37.6%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $10.0B | +503.0% |
| FY2024 | $1.7B | -83.2% |
| FY2023 | $9.9B | +143.6% |
| FY2022 | $4.1B | -5.0% |
| FY2021 | $4.3B | +5.3% |
| FY2020 | $4.1B | -71.2% |
| FY2019 | $14.1B | -19.9% |
| FY2018 | $17.6B | -20.5% |
| FY2017 | $22.2B | +45.4% |
| FY2016 | $15.3B | -31.2% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026